SCHEMBL359714

SCHEMBL359714

C=CCN(C(=O)C1CCCCC1)N1C=CC=CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5834889 0.68
SCHEMBL6669909 0.65
SCHEMBL18231941 0.61 ALDH1A1 (0.34)
SCHEMBL12158688 0.60 CES2 (0.38)
SCHEMBL17367607 0.60 ALDH1A1 (0.46)
SCHEMBL11160009 0.59 TP53 (0.35)
Propionic Acid SCHEMBL28425835 0.58 FFAR3 (0.36)
SCHEMBL24709169 0.57 DPP4 (0.33)
SCHEMBL10664271 0.56
SCHEMBL327566 0.55 CES2 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2407536-B1 ADP-ribosyl transferase fusion variant proteins BIOAXONE BIOSCIENCES INC (US) 2013-10-30 EP disclosed
EP-2407536-A9 ADP-ribosyl transferase fusion variant proteins Bioaxone Biosciences Inc. (US) 2013-03-13 EP disclosed
EP-2407536-A1 ADP-ribosyl transferase fusion variant proteins Bioaxone Therapeutique Inc. (CA) 2012-01-18 EP disclosed
US-7910554-B2 Biodrugs comprising polypeptides and carriers comprising bioadhesives such as fibrin, for treatment of vision defects; chimeric C3-like Rho antagonists and their use for promoting repair and neuron survival in injured mammalian central and peripheral nervous system and for treating cancer BIOAXONE THERAPEUTIQUE INC. (CA) 2011-03-22 US disclosed
US-7795218-B2 ADP-ribosyl transferase fusion variant proteins BIOAXONE THERAPEUTIQUE INC. (CA) 2010-09-14 US disclosed
EP-1377319-B1 FUSION PROTEINS BIOAXONE THERAPEUTIQUE INC (CA) 2010-09-08 EP disclosed
US-20090053190-A1 Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions BIOAXONE BIOSCIENCES INC. 2009-02-26 US disclosed
US-20080269120-A1 ADP-ribosyl transferase fusion variant proteins BIOAXONE THERAPEUTIQUE INC. (CA) 2008-10-30 US disclosed
US-7442686-B2 Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions BIOAXONE THERAPEUTIQUE INC. (CA) 2008-10-28 US disclosed
US-20070270340-A1 ADP-ribosyl transferase fusion variant proteins BIOAXONE BIOSCIENCES INC. 2007-11-22 US disclosed
US-7141428-B2 Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof BIOAXONE BIOSCIENCES INC. 2006-11-28 US disclosed
US-20050059595-A1 Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions BIOAXONE BIOSCIENCES INC. 2005-03-17 US disclosed
US-6855688-B2 ADP-ribosyl transferase fusion proteins, pharmaceutical compositions, and methods of use Bioaxone Thérapeutique Inc. (CA) 2005-02-15 US disclosed
US-20030103957-A1 Fusion proteins BIOAXONE BIOSCIENCES INC. 2003-06-05 US disclosed
EP-0370498-A2 Trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds and pharmaceutical use thereof YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1990-05-30 EP disclosed